Overview

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

Status:
Recruiting
Trial end date:
2025-12-17
Target enrollment:
Participant gender:
Summary
This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable). RBX7455 contains live intestinal microbes (active drug), which are obtained from healthy human stool and may restore the normal balance of microorganisms in the intestines through the transplant of live and beneficial microorganisms.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Cancer Institute (NCI)